ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z

Abstract Number: 1181

Gains in Cardiovascular Risk Knowledge Through Web Based Educational Intervention for Rheumatoid Arthritis Patients
Abstract Number: 1402

Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Abstract Number: 1779

Gap in Contraceptive Education to Females with Rheumatic Disease on Teratogenic Medications
Abstract Number: 0975

Gasdermin D Modulates Murine Lupus and Its Associated Organ Damage
Abstract Number: 0267

Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?
Abstract Number: 0821

Gender and Discontinuation of Biologic DMARDs in Patients with Rheumatoid Arthritis: Data from the Mexican Biologics Registry
Abstract Number: 0876

Gender Differences in Baseline Clinical Characteristics Among Patients with Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis: Data from 3 Randomized Ixekizumab Controlled Trials
Abstract Number: 1703

Gender Equity in Academic Rheumatology – Is There a Gender Gap at European Rheumatology Congresses?
Abstract Number: 0034

Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis
Abstract Number: 1580

Generalized Immune Activation in Structures Related to PMR or GCA on PET/CT Assessment Does Not Occur in Immune Checkpoint Inhibitor-Treated Patients Who Do Not Go on to Develop Rheumatic Immune-Related Adverse Events
Abstract Number: 0301

Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus
Abstract Number: 1862

Genetic Influences on Occurrence of Axial Spondyloarthritis (axSpA) in First-degree Relatives During a Prospective Study Lasting 35 Years
Abstract Number: 0494

Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients
Abstract Number: 1669

Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Abstract Number: 0982

Genetics of Avascular Necrosis in Children and Adults with Systemic Lupus Erythematosus
Abstract Number: 1954

Genome-wide Association Study of Sjögren’s Syndrome Identifies Ten New Risk Loci
Abstract Number: 0283

Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Abstract Number: 0661

Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Abstract Number: 0500

Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis
Abstract Number: 2037

Geographic Distribution and Environmental Triggers of Systemic Sclerosis in Massachusetts
Abstract Number: 0086

Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers
Abstract Number: 0043

Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity
Abstract Number: 0005

Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists
Abstract Number: 0238

Gestational Desire and Certolizumab Pegol in Patients with Chronic Inflammatory Rheumatic Disease. Preliminary Results of the GESTAMAD Cohort
Abstract Number: 1257

Gestational Diabetes Mellitus in Pregnant Women with Systemic Lupus Erythematosus
Abstract Number: 1932

Giant Cell Arteritis – the Relationship Between the Extensiveness of Vasculitis and the Clinical Presentation
Abstract Number: 1077

Glucagon-like Peptide-1 Receptor Agonist Suppresses Muscle Inflammation and Muscle Fiber Death, and Ameliorates Muscle Weakness in Experimental Polymyositis
Abstract Number: 1224

Glucocorticoid Reduction in Different Profiles of Patients with Rheumatoid Arthritis and Treatment with Sarilumab
Abstract Number: 0129

Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density
Abstract Number: 0109

Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Abstract Number: 1682

Goal-Setting Improves Transition Readiness in Adolescents with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus
Abstract Number: 0578

Going Digital Due to COVID 19 Crisis: A Rapid Reorganisation of Medication Clinics
Abstract Number: 0657

Gout and Heart Failure in the US
Abstract Number: 0681

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Abstract Number: 1573

Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Abstract Number: 0600

Gout Increases Length of Stay in Patients Hospitalized for Heart Failure Exacerbation
Abstract Number: 0673

Gout Is an Independent Risk Factor for Undergoing an Amputation Procedure
Abstract Number: 0667

Gout Management Beyond Prescription Writing: The Role of the Pharmacist
Abstract Number: 0853

Gradual Glucocorticoid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus
Abstract Number: 0259

Guillain-Barré Syndrome in Systemic Lupus Erythematosus – Results of a Nationwide Analysis
Abstract Number: 0888

Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naïve Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study
Abstract Number: 0908

Guselkumab Efficacy in Adult Patients with Active Psoriatic Arthritis by Baseline Demographic and Disease Characteristics: Pooled Results of Two Phase 3, Randomized, Placebo-Controlled Studies
Abstract Number: 0332

Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Abstract Number: 0367

Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
Abstract Number: 1349

Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Abstract Number: 0370

Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1
Abstract Number: 1344

Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced
Abstract Number: 1310

Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Abstract Number: 1971

Gut Microbiome Transplantation from MRL/MpJ Mice Prevents Post-Traumatic Osteoarthritis in C57BL6/J Mice

Jump to: View All • a b c d e f [g] h i j k l m n o p q r s t u v w x y z